Aarti Drugs Ltd Analyst Rating
based on 1 analysts
100.00%
Buy
0.00%
Hold
0.00%
Sell
Based on 1 analysts offering long term price targets for Aarti Drugs Ltd. An average target of ₹555
Source: S&P Global Market Intelligence
Aarti Drugs Ltd Share analysis
Aarti Drugs Ltd price forecast by 1 analysts
Upside of20.69%
High
₹555
Target
₹555.00
Low
₹555
Aarti Drugs Ltd target price ₹555, a slight upside of 20.69% compared to current price of ₹454.75. According to 1 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Aarti Drugs Ltd revenue growth forecast
Expected growth rate Q1, FY2026:13.48%
Forecast
Actual
Including amortisation and stock based compensations
Aarti Drugs Ltd EPS growth forecast
EPS estimate Q1, FY2026:44.77%
Forecast
Actual
Source: S&P Global Market Intelligence
Aarti Drugs Ltd Performance
Day's Low
Day's High
₹449.85₹460.952 Week's Low
52 Week's High
₹431.05₹635
| Returns % | |
| 1 Month Return | -7.1 % |
| 3 Month Return | -13.89 % |
| 1 Year Return | -2.65 % |
| Market Stats | |
| Previous Close | ₹459.85 |
| Open | ₹459.90 |
| Volume | 1.55L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹4,227.63Cr |
Aarti Drugs Ltd Key Statistics
| P/E Ratio | 27.72 |
| PEG Ratio | -9.53 |
| Market Cap | ₹4,227.63 Cr |
| P/B Ratio | 3.39 |
| EPS | 18.66 |
| Dividend Yield | 0.23 |
| Sector | Pharmaceuticals |
| ROE | 12.39 |
Aarti Drugs Ltd Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹4,227.63 Cr | 50.15% | 0.64 | ₹171 Cr | ₹2,528 Cr | |
| HOLD | ₹32,572.86 Cr | 131.85% | 0.52 | ₹300 Cr | ₹1,051 Cr | |
| BUY | ₹18,008.87 Cr | 29.69% | 0.57 | ₹72 Cr | ₹6,702 Cr | |
| NA | ₹6,359.97 Cr | 4.48% | 0.79 | -₹388 Cr | ₹75 Cr | |
| BUY | ₹16,029.93 Cr | 50.12% | 0.68 | ₹218 Cr | ₹1,296 Cr |
Aarti Drugs Ltd Mutual Fund Holdings
About Aarti Drugs Ltd
Share Price: ₹454.75 per share as on 21 Nov, 2024 04:01 PM
Market Capitalisation: ₹4,227.63Cr as of today
Revenue: ₹598.33Cr as on September 2024 (Q3 24)
Net Profit: ₹34.96Cr as on September 2024 (Q3 24)
Listing date: 03 Oct, 1996
Chairperson Name: Prakash M Patil
| Organisation | Aarti Drugs Ltd |
| Headquarters | Mumbai |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Aarti Drugs Ltd
Aarti Drugs Faces Decline After Weak Q2 Results - 25 Oct, 2024
Aarti Drugs reported significant declines in revenue and profit for Q2 FY25, leading to a drop in share prices. Consolidated net profit fell 11.57%, and standalone sales decreased 5.96% YoY. Investor concerns grew as the company faced challenging financial results.
Aarti Drugs Gains GMP Certification, Shares Rise - 04 Oct, 2024
Aarti Drugs' subsidiary, Pinnacle Life Science, received a GMP compliance certificate from UK MHRA, enabling UK exports. Shares rose 3% following the announcement.
Insights on Aarti Drugs Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTProfit Spike
Netprofit is up for the last 2 quarters, 33.24 Cr → 35.01 Cr (in ₹), with an average increase of 5.1% per quarter
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 5.70% to 6.25% in Sep 2024 quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 2 quarters, 556.45 Cr → 599.81 Cr (in ₹), with an average increase of 7.2% per quarter
NO EFFECTAgainst Peers
In the last 1 year, Divis Laboratories Ltd has given 58.6% return, outperforming this stock by 61.2%
- NO EFFECT
Retail Holding Unchanged
Retail Investor holdings remained unchanged at 34.02% of holdings in Sep 2024 quarter
- NO EFFECT
Against Peers
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 130.6% return, outperforming this stock by 139.7%
NEGATIVE IMPACTFII Holding Down
Foreign Institutions have decreased holdings from 2.96% to 2.50% in Sep 2024 quarter
- NEGATIVE IMPACT
Price Dip
In the last 3 years, AARTIDRUGS stock has moved down by -9.1%
- NEGATIVE IMPACT
Promoter Holding Down
Promoters have decreased holdings from 55.67% to 55.64% in Sep 2024 quarter
Aarti Drugs Ltd Financials
Index Inclusions
Aarti Drugs Ltd Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 55.64% | ||
| Foreign Institutions | 2.5% | ||
| Mutual Funds | 6.25% | 9.64 | |
| Retail Investors | 34.02% | 0.00 | |
| Others | 1.58% |
Aarti Drugs Ltd Key Indicators
Aarti Drugs Ltd Valuation
Aarti Drugs Ltd in the last 5 years
Lowest (8.29x)
March 31, 2020
Today (27.72x)
November 19, 2024
Industry (54.42x)
November 19, 2024
Highest (57.24x)
August 24, 2020
Aarti Drugs Ltd Earnings and Dividends
Aarti Drugs Ltd Earnings Results
Aarti Drugs Ltd’s net profit fell -11.57% since last year same period to ₹35.01Cr in the Q2 2024-2025. On a quarterly growth basis, Aarti Drugs Ltd has generated 5.32% jump in its net profits since last 3-months.
Read More about Earnings ResultsAarti Drugs Ltd Dividends January,2024
In the quarter ending December 2023, Aarti Drugs Ltd has declared dividend of ₹1 - translating a dividend yield of 0.44%.
Read More about Dividends
Aarti Drugs Ltd Technicals Summary
Bearish
Neutral
Bullish
Aarti Drugs Ltd is currently in a Bearish trading position according to technical analysis indicators.
FAQs on Aarti Drugs Ltd
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Aarti Drugs Ltd shares.
Aarti Drugs Ltd (AARTIDRUGS) share price today is ₹454.75
Aarti Drugs Ltd is listed on NSE
Aarti Drugs Ltd is listed on BSE
- Today’s highest price of Aarti Drugs Ltd is ₹460.9.
- Today’s lowest price of Aarti Drugs Ltd is ₹449.85.
PE Ratio of Aarti Drugs Ltd is 27.72
PE ratio = Aarti Drugs Ltd Market price per share / Aarti Drugs Ltd Earnings per share
Today’s traded volume of Aarti Drugs Ltd(AARTIDRUGS) is 1.55L.
Today’s market capitalisation of Aarti Drugs Ltd(AARTIDRUGS) is ₹4227.63Cr.
| Aarti Drugs Ltd(AARTIDRUGS | Price |
|---|---|
52 Week High | ₹635 |
52 Week Low | ₹431.05 |
Aarti Drugs Ltd(AARTIDRUGS) share price is ₹454.75. It is down -28.39% from its 52 Week High price of ₹635
Aarti Drugs Ltd(AARTIDRUGS) share price is ₹454.75. It is up 5.50% from its 52 Week Low price of ₹431.05
| Aarti Drugs Ltd(AARTIDRUGS | Returns |
|---|---|
1 Day Returns | -5.1% |
1 Month Returns | -7.1% |
3 Month Returns | -13.89% |
1 Year Returns | -2.65% |